Lithium cocrystal - Alzamend Neuro
Alternative Names: AL-001-Alzamend Neuro; LiProSal; LiProSalTMLatest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator University of South Florida
- Developer Alzamend Neuro
- Class Alkali metals; Antidementias; Antidepressants; Antimanics; Antipsychotics; Light metals; Small molecules
- Mechanism of Action Neuron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Alzheimer's disease
- Preclinical Bipolar disorders; Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 12 Dec 2024 Alzamend Neuro in partnership with Massachusetts General Hospital plans five phase II trials in Neurodegenerative and Neuropsychiatric disorders in 2025
- 19 Nov 2024 Adverse effects and pharmacodynamics data from preclinical studies in Alzheimer's disease released by Alzamend Neuro
- 26 Aug 2024 Alzamed Neuro plans the phase IIa AL001-PTSD01 trial for Post traumatic stress disorder in USA in 1H of 2025 (Alzamend Neuro pipeline, August 2024)